Canet, F.; Iannantuoni, F.; Marañon, A.M.d.; Díaz-Pozo, P.; López-Domènech, S.; Vezza, T.; Navarro, B.; Solá, E.; Falcón, R.; Bañuls, C.;
et al. Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes? Antioxidants 2021, 10, 1228.
https://doi.org/10.3390/antiox10081228
AMA Style
Canet F, Iannantuoni F, Marañon AMd, Díaz-Pozo P, López-Domènech S, Vezza T, Navarro B, Solá E, Falcón R, Bañuls C,
et al. Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes? Antioxidants. 2021; 10(8):1228.
https://doi.org/10.3390/antiox10081228
Chicago/Turabian Style
Canet, Francisco, Francesca Iannantuoni, Aránzazu Martínez de Marañon, Pedro Díaz-Pozo, Sandra López-Domènech, Teresa Vezza, Blanca Navarro, Eva Solá, Rosa Falcón, Celia Bañuls,
and et al. 2021. "Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?" Antioxidants 10, no. 8: 1228.
https://doi.org/10.3390/antiox10081228
APA Style
Canet, F., Iannantuoni, F., Marañon, A. M. d., Díaz-Pozo, P., López-Domènech, S., Vezza, T., Navarro, B., Solá, E., Falcón, R., Bañuls, C., Morillas, C., Rocha, M., & Víctor, V. M.
(2021). Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes? Antioxidants, 10(8), 1228.
https://doi.org/10.3390/antiox10081228
